Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.
about
Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiencyFactor XI and contact activation as targets for antithrombotic therapyBleeding related to disturbed fibrinolysisCystamine preparations exhibit anticoagulant activityCrosslinking decreases the hemocompatibility of decellularized, porcine small intestinal submucosa.Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitorInfluence of Interleukin-1 Beta on Platelet-Poor Plasma Clot Formation: A Potential Impact on Early Bone Healing.Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.Why factor XI deficiency is a clinical concern.Preanalytic processing of rat plasma influences thrombin generation and fibrinolysis assays.The hemostatic role of factor XI.Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficiency.Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein.The role of rotational thromboelastometry in assessment of haemostasis during pregnancy in women with factor XI deficiency.In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency.Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?Canine Neutrophil Extracellular Traps Enhance Clot Formation and Delay Lysis.Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.Fibrinogen and Fibrin in Hemostasis and Thrombosis.Multimodal assessment of non-specific hemostatic agents for apixaban reversal
P2860
Q27003801-F2FDCD86-E322-4683-A44A-ABC031117DAAQ27024190-7DC5B926-ABF0-4EF6-B856-59EC42C03089Q28070127-FDF92945-AB12-46EF-87AD-DEBF5EC6E02DQ34473794-8FDA4CB8-2901-485A-B1B3-6BFF7AFC67B6Q35019631-0A48ADBF-CBA0-4399-8F60-882AB77EB164Q35126274-DD84692E-5ADC-4E09-98A6-8CB6A1B05344Q35933749-A0A7F1B5-3714-4CCA-88A5-3A4B69D93E7AQ36169665-0B9F91DE-6AD6-43C5-BB37-54DFB9BC06ADQ37108888-D5C3723C-70F2-400A-8F59-FFA3227B2ACCQ38637310-8284D9AA-5BEC-4103-84E8-9C7CD1CFD8C9Q38840382-BAD2438D-745F-4627-AC73-54993AFF3C36Q45863678-285C2B52-C25E-46D9-BEFA-964D3FC2BFA8Q45869456-4E4F3D3D-A356-4D19-90B7-689FBB28B601Q45880495-79F27BF3-B67D-40D5-A822-BF4F1B669ED2Q45880602-A427819F-CE77-4AA9-90B2-AE4EFC3BED9FQ45885169-74B8466F-3C61-40FD-8AA8-B7629A3B7C65Q47162354-D4BCA431-7071-4142-B0F4-11B982D81662Q51084109-BE33CE92-58CA-4F29-B30D-BAF4F2CB0BC0Q53782006-53BB22A0-A0E2-46FE-8D4F-E2A2D761CE00Q54842287-FCECB87C-01E0-42E0-BEE9-D38FC15FEE0CQ59268547-5FA18DA4-4A7E-4F55-9514-B1DAEBFB76FD
P2860
Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@ast
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@en
type
label
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@ast
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@en
prefLabel
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@ast
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@en
P2093
P2860
P356
P1476
Abnormal plasma clot structure ...... h severe factor XI deficiency.
@en
P2093
A S Wolberg
U Seligsohn
P2860
P304
P356
10.1111/JTH.12600
P577
2014-06-19T00:00:00Z